Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR+56.6%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+56.6%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
9.4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 38.32% |
| Q2 2025 | 4.15% |
| Q1 2025 | 2.18% |
| Q4 2024 | 14.70% |
| Q3 2024 | 20.27% |
| Q2 2024 | -6.54% |
| Q1 2024 | -3.12% |
| Q4 2023 | 20.40% |
| Q3 2023 | -7.47% |
| Q2 2023 | 37.27% |
| Q1 2023 | -95.21% |
| Q4 2022 | 13.74% |
| Q3 2022 | -25.24% |
| Q2 2022 | -147.51% |
| Q1 2022 | 57.50% |
| Q4 2021 | -59.14% |
| Q3 2021 | -17.15% |
| Q2 2021 | 18.00% |
| Q1 2021 | 13.42% |
| Q4 2020 | -68.34% |
| Q3 2020 | 4.07% |
| Q2 2020 | 4.77% |
| Q1 2020 | -57.67% |
| Q4 2019 | 38.92% |
| Q3 2019 | 24.04% |
| Q2 2019 | -125.62% |
| Q1 2019 | -8.06% |
| Q4 2018 | -93.71% |
| Q3 2018 | 43.06% |
| Q2 2018 | 37.67% |
| Q1 2018 | -48.14% |
| Q4 2017 | -281.31% |
| Q3 2017 | 78.66% |
| Q2 2017 | 11.23% |
| Q1 2017 | -121.15% |
| Q4 2016 | 52.72% |
| Q3 2016 | -4.74% |
| Q2 2016 | 5.63% |
| Q1 2016 | -35.07% |
| Q4 2015 | 9.41% |